Table 1 Patient characteristics

From: Non-T-cell-depleted HLA haploidentical stem cell transplantation based on feto-maternal microchimerism in pediatric patients with advanced malignancies

Case

Age (years)

Diagnosis

Status

Donor

HLA mismatch (number of loci)

Microchimerism a

     

GVHD

HVG

Patient

Donor

 1

7

JMML

Primary refractory

Mother

1

1

+

NEb

 2

6

ALL

CR1 (advanced remission)

NIMA-mismatched sibling

1

2

−

+

 3

11

ALL

Rejection after UCBT (CR2)

Mother

2

2

NE

+

 4

16

MLL

Refractory relapse after UCBT

Mother

2

2

−

+

 5

14

CML

Blastic phase

Mother

2

2

−

+

 6

6

ALL

Rejection after UCBT (Rel 1)

Mother

3

0

NE

+

 7

17

t-AML

CR1

Mother

3

3

−

−

 8

7

ALL

Rel 2

Mother

1

0

NE

+

 9

5

NB

Refractory relapse after auto-PBSCT

Mother

3

3

−

+

10

9

RAEB-t

Rejection after UCBT (primary refractory)

NIMA-mismatched sibling

2

2

ND

+

11

8

RS

Refractory after auto-PBSCT

Mother

2

1

NE

−

  1. JMML=juvenile myelomonocytic leukemia; ALL=acute lymphocytic leukemia; MLL=mixed lineage leukemia; CML=chronic myeloid leukemia; t-AML=therapy-related acute myeloid leukemia; NB=neuroblastoma; RS=rhabdomyosarcoma; RAEB-t=refractory anemia with excess of blasts in transformation; CR1=first complete remission; CR2=second complete remission; Rel 1=first relapse; Rel 2=second relapse; UCBT=unrelated cord blood transplantation; PBSCT=peripheral blood stem cell transplantation; NE=not evaluable; ND=not done.
  2. a+, detectable; −, undetectable.
  3. bPresence of inherited paternal antigens could not technically be confirmed because the appropriate detection primer could not be used since the mother was HLA (A2, A24) and the patient was HLA (A2, −).
Back to article page